{"id":62216,"date":"2026-04-02T22:41:19","date_gmt":"2026-04-02T14:41:19","guid":{"rendered":"https:\/\/flcube.com\/?p=62216"},"modified":"2026-04-02T22:41:21","modified_gmt":"2026-04-02T14:41:21","slug":"sanli-pharmaceutical-transfers-marketing-rights-for-16-drugs-to-hanfang-pharmaceutical-in-rmb-2-million-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62216","title":{"rendered":"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal"},"content":{"rendered":"\n<p><strong>Guizhou Sanli Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603439:SHA\">SHA: 603439<\/a>) announced the transfer of <strong>marketing authorizations and comprehensive rights<\/strong> for <strong>16 pharmaceutical products<\/strong>, including <strong>cisplatin sodium chloride injection<\/strong>, to fellow Guizhou-based company <strong>Guizhou Hanfang Pharmaceutical Co., Ltd.<\/strong> in a transaction valued at <strong>RMB 2 million (USD 290,533)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset Category<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Products<\/strong><\/td><td>16 drugs including cisplatin sodium chloride injection<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>RMB 2 million (USD 290,533)<\/td><\/tr><tr><td><strong>Buyer<\/strong><\/td><td>Guizhou Hanfang Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Seller<\/strong><\/td><td>Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439)<\/td><\/tr><tr><td><strong>Rights Status<\/strong><\/td><td>Complete, exclusive, and unencumbered<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-comprehensive-asset-transfer-package\">Comprehensive Asset Transfer Package<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-rights\">Regulatory Rights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Full marketing authorization holder status<\/li>\n\n\n\n<li>Drug registration approvals<\/li>\n\n\n\n<li>Re-registration approvals<\/li>\n\n\n\n<li>Supplementary application approvals<\/li>\n\n\n\n<li>All related regulatory documentation<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-global-commercialization-rights\">Global Commercialization Rights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Research and development rights<\/li>\n\n\n\n<li>Manufacturing and contract manufacturing rights<\/li>\n\n\n\n<li>Sales and marketing rights<\/li>\n\n\n\n<li>Import and export rights<\/li>\n\n\n\n<li>Packaging rights<\/li>\n\n\n\n<li>Licensing rights<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-technical-documentation-amp-ip\">Technical Documentation &amp; IP<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete technical documentation<\/li>\n\n\n\n<li>Manufacturing processes and quality standards<\/li>\n\n\n\n<li>Stability and impurity study data<\/li>\n\n\n\n<li>Validation documents and CTD registration dossiers<\/li>\n\n\n\n<li>Intellectual property portfolio including:<\/li>\n\n\n\n<li>Patents<\/li>\n\n\n\n<li>Trademarks<\/li>\n\n\n\n<li>Copyrights<\/li>\n\n\n\n<li>Know-how and trade secrets<\/li>\n\n\n\n<li>Exclusive rights to use and dispose of all IP assets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-infrastructure\">Commercial Infrastructure<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Customer resources and relationships<\/li>\n\n\n\n<li>Distribution channel resources<\/li>\n\n\n\n<li>Qualified suppliers of packaging materials and excipients<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-post-marketing-obligations\">Post-Marketing Obligations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adverse reaction monitoring responsibilities<\/li>\n\n\n\n<li>Pharmacovigilance systems and data<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-sanli-pharmaceutical\">For Sanli Pharmaceutical<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Rationalization<\/strong>: Streamlines product portfolio to focus on core therapeutic areas<\/li>\n\n\n\n<li><strong>Capital Generation<\/strong>: Converts non-core assets into immediate cash proceeds<\/li>\n\n\n\n<li><strong>Operational Efficiency<\/strong>: Reduces regulatory and compliance burden for transferred products<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-hanfang-pharmaceutical\">For Hanfang Pharmaceutical<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Acquires established products with existing market presence<\/li>\n\n\n\n<li><strong>Regulatory Shortcuts<\/strong>: Gains immediate marketing authorization without lengthy approval processes<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Inherits existing customer base and distribution channels<\/li>\n\n\n\n<li><strong>Manufacturing Capabilities<\/strong>: Accesses proven manufacturing processes and technical know-how<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-implications\">Market Context &amp; Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chinese-pharmaceutical-industry-trends\">Chinese Pharmaceutical Industry Trends<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Consolidation Wave<\/strong>: Reflects broader industry trend toward portfolio optimization and strategic asset transfers<\/li>\n\n\n\n<li><strong>Regional Clustering<\/strong>: Both companies based in Guizhou province, demonstrating regional pharmaceutical ecosystem development<\/li>\n\n\n\n<li><strong>Generic Drug Market<\/strong>: Cisplatin and similar products represent mature generic segments with stable cash flows<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-transaction-valuation-analysis\">Transaction Valuation Analysis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Per-Product Value<\/strong>: Approximately RMB 125,000 (USD 18,158) per drug product<\/li>\n\n\n\n<li><strong>Asset Quality<\/strong>: Comprehensive rights package justifies premium over simple marketing authorization transfers<\/li>\n\n\n\n<li><strong>Market Positioning<\/strong>: Represents typical valuation range for established generic products in Chinese market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-significance\">Regulatory Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MAH System Implementation<\/strong>: Transaction leverages China&#8217;s Marketing Authorization Holder (MAH) system reforms<\/li>\n\n\n\n<li><strong>Seamless Transition<\/strong>: Comprehensive rights transfer ensures uninterrupted patient access to essential medicines<\/li>\n\n\n\n<li><strong>Compliance Assurance<\/strong>: Full technical documentation transfer maintains product quality and safety standards<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding strategic rationale, market trends, and transaction implications. Actual outcomes may vary based on integration success, market dynamics, and regulatory compliance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603439_20260402_LXPJ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603439_20260402_LXPJ.\"><\/object><a id=\"wp-block-file--media-f32305a5-0ef8-4187-bd8a-14b934349879\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603439_20260402_LXPJ.pdf\">603439_20260402_LXPJ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603439_20260402_LXPJ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f32305a5-0ef8-4187-bd8a-14b934349879\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4678,4676,4677],"class_list":["post-62216","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hanfang-pharmaceutical","tag-sanli-pharmaceutical","tag-sha-603439"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive rights for 16 pharmaceutical products, including cisplatin sodium chloride injection, to fellow Guizhou-based company Guizhou Hanfang Pharmaceutical Co., Ltd. in a transaction valued at RMB 2 million (USD 290,533).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal\" \/>\n<meta property=\"og:description\" content=\"Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive rights for 16 pharmaceutical products, including cisplatin sodium chloride injection, to fellow Guizhou-based company Guizhou Hanfang Pharmaceutical Co., Ltd. in a transaction valued at RMB 2 million (USD 290,533).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T14:41:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T14:41:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal\",\"datePublished\":\"2026-04-02T14:41:19+00:00\",\"dateModified\":\"2026-04-02T14:41:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62216\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hanfang Pharmaceutical\",\"Sanli Pharmaceutical\",\"SHA: 603439\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62216#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62216\",\"name\":\"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-02T14:41:19+00:00\",\"dateModified\":\"2026-04-02T14:41:21+00:00\",\"description\":\"Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive rights for 16 pharmaceutical products, including cisplatin sodium chloride injection, to fellow Guizhou-based company Guizhou Hanfang Pharmaceutical Co., Ltd. in a transaction valued at RMB 2 million (USD 290,533).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62216\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive rights for 16 pharmaceutical products, including cisplatin sodium chloride injection, to fellow Guizhou-based company Guizhou Hanfang Pharmaceutical Co., Ltd. in a transaction valued at RMB 2 million (USD 290,533).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62216","og_locale":"en_US","og_type":"article","og_title":"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal","og_description":"Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive rights for 16 pharmaceutical products, including cisplatin sodium chloride injection, to fellow Guizhou-based company Guizhou Hanfang Pharmaceutical Co., Ltd. in a transaction valued at RMB 2 million (USD 290,533).","og_url":"https:\/\/flcube.com\/?p=62216","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-02T14:41:19+00:00","article_modified_time":"2026-04-02T14:41:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal","datePublished":"2026-04-02T14:41:19+00:00","dateModified":"2026-04-02T14:41:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62216"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hanfang Pharmaceutical","Sanli Pharmaceutical","SHA: 603439"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62216#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62216","url":"https:\/\/flcube.com\/?p=62216","name":"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-02T14:41:19+00:00","dateModified":"2026-04-02T14:41:21+00:00","description":"Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive rights for 16 pharmaceutical products, including cisplatin sodium chloride injection, to fellow Guizhou-based company Guizhou Hanfang Pharmaceutical Co., Ltd. in a transaction valued at RMB 2 million (USD 290,533).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62216"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62216\/revisions"}],"predecessor-version":[{"id":62223,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62216\/revisions\/62223"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}